Botulinum toxin therapy has emerged as a treatment modality for a variety of spasticor contracture-related muscle diseases. Its safety has been proven for long-term use in the treatment of benign essential bleopharospasm, hemifacial spasm, and certain types of strabismus. Recent approval from the Federal Drug Administration should make botulinum toxin available for use in a greater number of patients.